Further research is merited, but based on these results, clinical trials could be considered using BYL-719 in combination with everolimus for basal-like tumors with PI3K pathway overactivity, either through PTEN loss or pathogenic PIK3CA and the combinations of either dronedarone or afatinib with BYL-719 should be considered for testing for patients with basal-like breast cancer with pathogenic PIK3CA. This evidence concerns the gene PTEN and breast cancer.